Description

Release Date: 10/07/2009
Expiration Date: 10/07/2010

Guidelines from the 7th Report of the Joint National Committee on Prevention, Detention, Evaluation and Treatment of High Blood Pressure (JNC-7) recommend treatment goals should be <140/90 mmHg or <130/80 mmHg for patients with diabetes or chronic kidney disease. Despite the increased percentage of people who are aware of their hypertension and on treatment for it, 68% of the total remains above the therapeutic guidelines for blood pressure (BP) goals, according to date from the National Health and Nutrition Examination Survey (NHANES). Those not meeting the therapeutic BP goals fall into the following three categories: unaware of their condition (~31%), aware but not treated (~11%), treated but remain above the target of 140/90 mm Hg (~27% of all hypertensive persons). The percentage of patients with diabetes with blood pressure meeting the recommended levels by the American Diabetes Association (systolic blood pressure (SBP) <130 mm Hg and diastolic blood pressure (DBP) <80 mm Hg) did not witness any significant change between NHANES III conducted in 1988-1994 and NHANES 1999-2000 (29.0% and 35.8%, respectively). Hypertension control rates remain lower among ethnic minorities than whites, especially among adults under age 60.

Learning Objectives

Upon completion of this program, participants should be able to:

• Improve management of hypertension
• Develop a treatment algorithm for the aggressive control of the blood pressure in patients with 1-2 risk factors, and those with metabolic syndrome
• Describe the use of ACE inhibitors, ACE inhibitors, angiotensin receptor blockers, beta blockers and calcium channel blockers, alone or in-combination, to achieve treatment goals.
• Understand treatment considerations for patients with multiple risk factors
• Modifications to treatment goals
• Common comorbidities and how to treat
• Drug-drug interactions considerations

Faculty

Moderator

Adolph M Hutter Jr, MD, MACC, FAHA, FESC
Clinical Cardiologist
Massachusetts General Hospital
Professor of Medicine
Harvard Medical School

Faculty

Randal Zusman, MD
Massachusetts General Hospital

Elijah Saunders, MD, FACC, FACP
Professor of Medicine, Cardiology, University of Maryland School of Medicine

Stephen Swartz, MD
Hypertension-Endocrine Division at Brigham and Women's Hospital

Faculty Disclosures

Dr. Hutter receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Dr. Swartz receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Dr. Zusman  is on the speakers bureau, advisory board and does research support for BMS, SanofiAventis, Novartis, Daichii Sankyo, Eli Lilly, Pfizer, Forest, Astra Zeneca, GlaxoSmithKline. Dr. Zusman receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Dr. Saunders received honoraria as a consultant, speaker and research for Pfizer, Novartis, Forest, BMS and Sanofi-Aventis. He receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website www.mghcme.org.

Accreditation

Release Date: 10/07/2009
Expiration Date: 10/07/2010

ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the Essential Areas and policies of the Accreditation Council for Continuing Medical Education through the joint sponsorship and St. Luke’s and Roosevelt Hospitals and Reed Medical Education. Beth Israel Medical Center & St. Luke’s and Roosevelt Hospitals are accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

CREDIT DESIGNATION
Beth Israel Medical Center designates this educational activity for a maximum of 1.00 AMA PRA Category 1 Credits TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

POLICY ON FACULTY AND PROVIDER DISCLOSURE
It is the policy of Beth Israel Medical Center and St. Luke's and Roosevelt Hospitals that faculty and providers disclose real or apparent conflicts of interest relating to the topics of this educational activity, and also disclose discussions of unlabeled/unapproved uses of drugs or devices during their presentation(s). Beth Israel Medical Center and St. Luke's and Roosevelt Hospitals have established policies in place that will identify and resolve all conflicts of interest prior to this educational activity.

Resolution of Conflict of Interest (COI)
It is the policy of Beth Israel Medical Center and St. Luke's and Roosevelt Hospitals has implemented a process to resolve COI for each CME activity. In order to help ensure content objectivity, independence, fair balance, and that the content is aligned with the interest of the public,  MGH has resolved the conflict by Peer Review.

Faculty Disclosures
Dr. Hutter receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Dr. Swartz receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Dr. Zusman  is on the speakers bureau, advisory board and does research support for BMS, SanofiAventis, Novartis, Daichii Sankyo, Eli Lilly, Pfizer, Forest, Astra Zeneca, GlaxoSmithKline. Dr. Zusman receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Dr. Saunders received honoraria as a consultant, speaker and research for Pfizer, Novartis, Forest, BMS and Sanofi-Aventis. He receives honoraria from Reed Medical Education (a company working as a logistics collaborator for the MGH Psychiatry Academy). The education programs conducted by the MGH Psychiatry Academy were supported through Independent Medical Education (IME) grants from pharmaceutical companies co-supported programs along with participant tuition. Commercial entities supporting the MGH Psychiatry Academy in 2008 are listed on the Academy's website http://www.mghcme.org/.

Supporters

Our evidence-based curriculum is supported by educational grants from:

• 
  
•